Date | Price Target | Rating | Analyst |
---|---|---|---|
5/12/2023 | $10.00 → $4.00 | Overweight → Neutral | Piper Sandler |
8/3/2022 | $8.00 | Buy | Jefferies |
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
8-K - ImmunityBio, Inc. (0001326110) (Filer)
S-8 - ImmunityBio, Inc. (0001326110) (Filer)
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab) ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months Long-term survival was independent of PDL1 tumor status and independent of 2nd or 3rd line of therapy The data continues to validate the mechanism of action of ANKTIVA in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in pati
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial and clinical bladder cancer programs Filing process initiated with European Medicines Agency (EMA) for regulatory approval of ANKTIVA in European Union countries Global filing for BCG naïve trial initiated (QUILT-2.005) in India ANKTIVA Non-Small Cell Lung Cancer (NSCLC) FDA meeting held in June 2024 ImmunityBio, Inc. ((IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company
The QUILT 502 trial is testing ImmunityBio's N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for endometrial cancer, a gynecological cancer with lower survival rates and limited effective post-second-line treatment. The AdHER2DC vaccine targets the HER2 protein, which is elevated in 30% of endometrial cancer. ANKTIVA, recently approved for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, is designed to activate the immune cells that kill tumor cells to provide long-term immune response. The Phase1/2 interventional study will enroll 60 participants with HER2-positive endometrial cancer (EC), who will also receive pembrolizumab and len
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week’s release of ‘San Guo: Mou Ding Tian Xia.’ Also, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price forecast. ImmunityBio, Inc. (NASDAQ:IBRX) shares jumped 22.36% on continued strength after the announcement of insurance coverage of ANKTIVA across multiple states with the first commercial doses administered. Sasol Ltd. (NYSE:SSL) shares escalated 20.89% after the company announced that the court ruled in favor of the company and TotalEnergies SE (NYSE:TTE) Marketing. Also, it
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program "A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC" Discussion about the basis for ANKTIVA's Breakthrough Therapy designation and the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. ((IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bl
QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus che
Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activates the body's natural killer (NK) and killer T-cell immune system to attack tumor cells Therapy stimulates memory T cells, leading to long duration of complete response exceeding 47 months and ongoing to date, with a median duration of response yet to be determined The percentage of patients with durable responses at 12 and 24 months exceeded the benchmark for magnitude of clinically meaningful results established by experts at the International Bladder Cancer Group (IBCG) ANKTIVA in combination with BCG is approved for maintenance therapy for up to 37 months with tolerable side effects ranging from 0%
ImmunityBio, Inc. ((IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Officer and President, will provide a business update after the formal business of the Annual Meeting has ended. All interested parties are welcome to attend the Annual Meeting and listen to the Company update. Non-stockholders can attend the vir
- Yun Han named Chief Accounting Officer and Interim Chief Financial Officer - - Initial Funding Expected This Week Under $60 Million Financing Agreement - Faraday Future Intelligent Electric Inc. ("Faraday Future" or the "Company") (NASDAQ:FFIE), a California-based global shared intelligent electric mobility ecosystem company, today announced the appointment of Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Ms. Han replaces Becky Roof, who served as interim Chief Financial Officer until October 12, 2022, and is assisting the Company to ensure an orderly transition. This press release features multimedia. View the full release here: htt
Biopharma leaders bring proven market development talents in urology and oncology to bolster company's commercialization plan and long-term growth plans Helen Luu, former CEO of Cell BT, is named ImmunityBio's first Chief Commercial Officer and brings a strong background in product commercialization in the urology market, business development, sales growth, and oncology market expansion. Sigrid Schreiner joins as Senior Vice President of Global Market Access, adding decades of market access experience to the leadership team, including the market launch of chemotherapy Abraxane®. ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced two key executive
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
4 - ImmunityBio, Inc. (0001326110) (Issuer)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)
Piper Sandler downgraded ImmunityBio from Overweight to Neutral and set a new price target of $4.00 from $10.00 previously
Jefferies initiated coverage of ImmunityBio with a rating of Buy and set a new price target of $8.00